MSL
ALDR

Mackay Shields LLC’s Alder Biopharmaceuticals ALDR Stock Holding History

Mackay Shields LLC’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-36,220
Closed -$460K – 1342
2018
Q1 		$460K Buy
+36,220
New +$524K ﹤0.01% 1128

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Mackay Shields LLC's ALDR Position: Q2 2018 in Review

Mackay Shields LLC sold out of Alder Biopharmaceuticals (ALDR) in Q2 2018, closing a stake of 36,220 shares — an estimated $460K sold.

Mackay Shields LLC first reported a position in ALDR in Q1 2018 and held it in 1 quarter. The position peaked at $460K in Q1 2018. 139 funds tracked by Wall St. Rank hold ALDR as of Q2 2018.

  • Mackay Shields LLC reported no remaining Alder Biopharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Mackay Shields LLC sold 36,220 Alder Biopharmaceuticals shares in Q2 2018, an estimated $460K.
  • Mackay Shields LLC first reported a position in Alder Biopharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Mackay Shields LLC's Alder Biopharmaceuticals position peaked at $460K in Q1 2018.
  • 139 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2018.

Based on Mackay Shields LLC's 13F filing for Q2 2018, filed 6 Aug 2018.